

Stem Cell Transplantation and Cellular Therapy

Disease	Key Entry Criteria	Trial Name & Treatment
CMV	Post HSCT 1 st episode of CMV either Primary or reactivation	Shire - Post HSCT primary or reactivation Maribavir vs Valganciclovir
AMADEUS	Study therapy commences 42 – 84 days post allo SCT. Adequately controlled GVHD – grade 2 or below	AMADEUS = oral azacitidine v placebo for AML/MDS as maintenance post allo SCT.
IMPACT COVID19	Post allo SCT with proven COVID19 within 72 hours of diagnosis	COVID19 = Non-interventional study evaluating role of immune and inflammatory response post allo SCT affected by COVID